4.73

6.77% 0.30

After Hours: 4.72 -0.01 -0.21%

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $4.73, with a volume of 119.79K. It is up +6.77% in the last 24 hours and up +0.42% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$4.43

Open:

$4.47

24h Volume:

119.79K

Relative Volume:

1.43

Market Cap:

$46.97M

Revenue:

$20.34M

Net Income/Loss:

$-24.52M

P/E Ratio:

-1.3227

EPS:

-3.5761

Net Cash Flow:

$-5.92M

1W Performance:

+22.22%

1M Performance:

+0.42%

6M Performance:

-7.82%

1Y Performance:

-19.16%

1-Day Range:

$4.421

$4.77

1-Week Range:

$3.88

$4.77

52-Week Range:

$3.68

$10.48

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2026-08-12

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	4.73	40.42M	20.34M	-24.52M	-5.92M	-3.5761
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

Jul 01, 2026

Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained - TipRanks

Jul 01, 2026

Jun 30, 2026

SCYNEXIS (SCYX) director Armando Anido granted stock units and options - Stock Titan

Jun 30, 2026

SCYNEXIS (SCYX) director receives new stock and option awards - Stock Titan

Jun 30, 2026

SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants - Stock Titan

Jun 30, 2026

Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135 - TradingView

Jun 30, 2026

Scynexis (SCYX) Launches Phase 1 Study for SCY-770 in Kidney Dis - GuruFocus

Jun 30, 2026

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times

Jun 30, 2026

Enterprise value to revenue forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Jun 30, 2026

Jun 29, 2026

Enterprise value to revenue forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Jun 29, 2026

Price to book forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Jun 29, 2026

Price to earnings forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Jun 29, 2026

Price to book forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Jun 29, 2026

Enterprise value to EBITDA forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView

Jun 29, 2026

Jun 28, 2026

Price to sales forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView

Jun 28, 2026

Jun 26, 2026

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes - TipRanks

Jun 26, 2026

SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale - Stock Titan

Jun 26, 2026